Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Narcolepsy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Narcolepsy Market.

Some of the key takeaways from the Narcolepsy Pipeline Report: https://www.delveinsight.com/sample-request/narcolepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Narcolepsy treatment therapies with a considerable amount of success over the years.
• Narcolepsy companies working in the treatment market are Orexia, Merck Sharp & Dohme, Jazz Pharmaceuticals, Takeda, Suven Life Sciences, Axsome Therapeutics, NLS Pharmaceutics Ltd, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, DE, USA, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Takeda, Alkermes, Inc., Pfizer, Balance Therapeutics, Avadel, and others, are developing therapies for the Narcolepsy treatment
• Emerging Narcolepsy therapies in the different phases of clinical trials are- ORX-750, MK 6552, JZP-441, TAK-925, SUVN-G3031, AXS 12, NLS-2, JZP258, TS-091, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, TAK-861, ALKS 2680, PF-03654746, BTD-001, FT218, and others are expected to have a significant impact on the Narcolepsy market in the coming years.
• In July 2025, Takeda revealed this week that its oral small-molecule candidate, oveporexton, designed to treat type I narcolepsy, demonstrated positive outcomes in two pivotal Phase III trials, potentially paving the way for regulatory approval. Type I narcolepsy is estimated to impact about 126,000 individuals in the U.S., though underdiagnosis suggests the true number may be higher. The condition arises from the loss of neurons that produce orexin, a neuropeptide essential for regulating wakefulness and REM sleep.
• In April 2025, According to data presented at the 2025 American Academy of Neurology (AAN) annual meeting, the investigational therapy AXS-12 (reboxetine) significantly decreased the frequency of weekly cataplexy episodes and other narcolepsy-related symptoms compared with placebo.
•

Narcolepsy Overview
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, sudden and uncontrollable episodes of falling asleep during the day, and disrupted nighttime sleep patterns. People with narcolepsy often experience sudden loss of muscle tone (cataplexy), vivid hallucinations while falling asleep or waking up (hypnagogic and hypnopompic hallucinations), and temporary paralysis when falling asleep or waking up (sleep paralysis).

Get a Free Sample PDF Report to know more about Narcolepsy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/narcolepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Narcolepsy Drugs Under Different Phases of Clinical Development Include:
• ORX-750: Orexia
• MK 6552: Merck Sharp & Dohme
• JZP-441: Jazz Pharmaceuticals
• TAK-925: Takeda
• SUVN-G3031: Suven Life Sciences
• AXS 12: Axsome Therapeutics
• NLS-2: NLS Pharmaceutics Ltd
• JZP258: Jazz Pharmaceuticals
• TS-091: Taisho Pharmaceutical
• SUVN-G3031: Suven Life Sciences Limited
• JNJ-17216498: Alza Corporation, DE, USA
• Modafinil: Cephalon
• sodium oxybate Orphan Medical
• THN102 300/3: Theranexus
• Mazindol: NLS Pharmaceutics
• TAK-861: Takeda
• ALKS 2680: Alkermes, Inc.
• PF-03654746 Pfizer
• BTD-001: Balance Therapeutics
• FT218: Avadel

Narcolepsy Route of Administration
Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Narcolepsy Molecule Type
Narcolepsy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Narcolepsy Pipeline Therapeutics Assessment
• Narcolepsy Assessment by Product Type
• Narcolepsy By Stage and Product Type
• Narcolepsy Assessment by Route of Administration
• Narcolepsy By Stage and Route of Administration
• Narcolepsy Assessment by Molecule Type
• Narcolepsy by Stage and Molecule Type

DelveInsight's Narcolepsy Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Narcolepsy product details are provided in the report. Download the Narcolepsy pipeline report to learn more about the emerging Narcolepsy therapies
https://www.delveinsight.com/sample-request/narcolepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Narcolepsy Therapeutics Market include:
Key companies developing therapies for Narcolepsy are - Novartis AG, Shionogi Inc., Takeda Pharmaceutical, Avadel Pharmaceuticals, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Inc, Teva Pharmaceuticals, Axsome Therapeutics Inc., XWPharma Ltd., and others.

Narcolepsy Pipeline Analysis:
The Narcolepsy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Narcolepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Narcolepsy Treatment.
• Narcolepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Narcolepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Narcolepsy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Narcolepsy drugs and therapies
https://www.delveinsight.com/sample-request/narcolepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Narcolepsy Pipeline Market Drivers
• Need for disease-specific treatment options, increasing research and developmental activities are some of the important factors that are fueling the Narcolepsy Market.

Narcolepsy Pipeline Market Barriers
• However, No standard specific cure for Narcolepsy and other factors are creating obstacles in the Narcolepsy Market growth.

Scope of Narcolepsy Pipeline Drug Insight
• Coverage: Global
• Key Narcolepsy Companies: Orexia, Merck Sharp & Dohme, Jazz Pharmaceuticals, Takeda, Suven Life Sciences, Axsome Therapeutics, NLS Pharmaceutics Ltd, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, DE, USA, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Takeda, Alkermes, Inc., Pfizer, Balance Therapeutics, Avadel, and others
• Key Narcolepsy Therapies: ORX-750, MK 6552, JZP-441, TAK-925, SUVN-G3031, AXS 12, NLS-2, JZP258, TS-091, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, TAK-861, ALKS 2680, PF-03654746, BTD-001, FT218, and others
• Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies
• Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.